When is the new weight loss injection available — and how do you access it?

What the clinical evidence established, and when regulators acted

NICE published its appraisal of tirzepatide (TA1026) on 23 December 2024, updated on 1 September 2025. The recommendation drew on SURMOUNT-1, a 72-week trial published in the New England Journal of Medicine, in which participants at the 15mg dose saw average body-weight reductions of around 20–21%. That evidence base is what put tirzepatide on the NICE list. Semaglutide (Wegovy injection) had already cleared that bar earlier, NICE TA875 was published in March 2023, recommending it within specialist weight management services for up to two years.

The more recent licensing decision worth knowing about is the MHRA's approval on 14 April 2026 of a dedicated single-dose 7.2mg Wegovy pen. Trials at that dose reported average weight loss of around 20.7% over 72 weeks, bringing semaglutide's ceiling noticeably closer to tirzepatide's. That pen is approved for adults with a BMI of 30 or above, the cardiovascular indication is not included. The starting dose still sits at 0.25mg; 7.2mg is the maximum your prescriber can move you toward. If you want a full picture of what weight loss injections are currently available and how they compare, that page sets it out clearly.

The licensing and NICE timelines matter because they are what trigger both NHS commissioning decisions and the private supply chain. Once a medicine is licensed and recommended, a regulated pharmacy can dispense it on a valid private prescription, which is why both Mounjaro and Wegovy have been accessible privately since their respective UK launches.

Where the NHS rollout currently stands

NHS access to Mounjaro in England is expanding in clearly defined cohorts, based on NICE TA1026's recommendations and NHS England's interim commissioning guidance. The qualifying conditions that determine cohort eligibility are: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes.

The first cohort (BMI 40 or above plus four or more of those five conditions) opened in June 2025. Cohort 2, covering BMI 35–39.9 plus four or more conditions, activated on 23 June 2026. A further phase, BMI 40-plus with three qualifying conditions, is expected around March 2027. For South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean backgrounds, the BMI thresholds sit 2.5 kg/m² lower at each stage.

From 1 April 2026 some GP practices can now prescribe under the new GP contract, though practice participation is optional and availability varies by area. Even within an eligible cohort, patients must join a supported programme with diet and activity guidance alongside the medicine. Meeting the numbers on paper does not guarantee a prescription, the clinical picture matters. Wegovy on the NHS remains routed through specialist weight management services, where waiting lists are commonly long. For a closer look at whether you can access the new weight loss injection through the NHS or privately, that page walks through both routes.

What the private route looks like, and why timing is different

Through a GPhC-registered online pharmacy, private access to these injections does not depend on NHS cohort dates. What it does depend on is clinical suitability, assessed by a qualified prescriber before anything is dispensed. At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber. They check your health history, any current medicines, and your weight (verified on video, not self-reported). If a prescription is appropriate, treatment is dispatched the same working day for orders placed before 12pm, arriving free with DPD the next working day in plain, unbranded packaging. You can tuck the pen straight into the fridge door when it arrives, there is nothing on the box that identifies the contents.

There are no subscriptions and no automatic renewals. Every repeat order goes through the same clinical re-review. If you are curious about when to take your injection during the week, or want to understand the routine side of treatment, that is worth reading alongside this. The cost of weight loss injections privately is covered separately, one transparent price includes the consultation, prescription, delivery, and aftercare.

To verify that any online pharmacy is legitimately registered, check the GPhC register directly at pharmacyregulation.org, registration number 9012878 for nume's pharmacy. The MHRA has warned publicly about fake weight loss pens sold online and via social media, some of which have contained insulin. Sellers offering these medicines without a prescription, at prices far below market rate, or with discount codes, are the red flags to watch for. Suspect sellers can be reported via the MHRA Yellow Card scheme.

What to do now if you are ready to explore treatment

If you have read this far, you probably have a specific situation in mind: NHS criteria you don't yet meet, a waiting list you'd rather not join, or straightforward curiosity about whether you'd be suitable now. The latest on the new weight loss injection covers the 2026 updates in more detail. Our safety overview is worth reading too, it covers common side effects, the January 2026 MHRA pancreatitis update, and what to watch for. A thorough picture of the broader weight loss treatment landscape is available if you want context before committing to anything.

These are prescription-only medicines. The right starting point is a free clinical consultation, not a checkout. Check your eligibility with our prescribers, it costs nothing and there is no obligation.